Discontinuation report TAZORAC
| Report ID | 150061 |
| Drug Identification Number | 02243895 |
| Brand name | TAZORAC |
| Common or Proper name | Tazarotene Cream |
| Company Name | ALLERGAN INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | TAZAROTENE |
| Strength(s) | 0.1% |
| Dosage form(s) | CREAM |
| Route of administration | TOPICAL TOPICAL |
| Packaging size | 30g, 3.5g |
| ATC code | D05AX |
| ATC description | ANTIPSORIATICS FOR TOPICAL USE |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2022-02-01 |
| Actual discontinuation date | 2022-02-25 |
| Remaining supply date | 2022-02-01 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2021-11-26 | English | Compare |
| v2 | 2021-11-26 | French | Compare |
| v3 | 2022-03-14 | English | Compare |
| v4 | 2022-03-14 | French | Compare |
Showing 1 to 4 of 4